{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:03:58Z","timestamp":1793160238134,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK118200"],"award-info":[{"award-number":["K23DK118200"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R03DK129558"],"award-info":[{"award-number":["R03DK129558"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK123704"],"award-info":[{"award-number":["P30DK123704"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015690","name":"South Carolina Clinical and Translational Research Institute, Medical University of South Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001450"],"award-info":[{"award-number":["UL1 TR001450"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.eprac.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:53:55Z","timestamp":1723121635000},"page":"1015-1022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Objective Measures of Cardiometabolic Risk and Advanced Fibrosis Risk Progression in Primary Care Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0914-3182","authenticated-orcid":false,"given":"Andrew D.","family":"Schreiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"Mauldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulugeta","family":"Gebregziabher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2024.08.002_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2024.08.002_bib2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.002_bib3","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.eprac.2024.08.002_bib4","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.002_bib5","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.002_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2024.08.002_bib7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dci21-0020","article-title":"Preparing for the NASH epidemic: a call to action","volume":"44","author":"Kanwal","year":"2021","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.eprac.2024.08.002_bib8","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2024.08.002_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.002_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.002_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.002_bib12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.eprac.2024.08.002_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3668","article-title":"Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis","volume":"39","author":"Ciccarelli","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"10.1016\/j.eprac.2024.08.002_bib14","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/liv.15404","article-title":"Management of NAFLD in primary care settings","volume":"42","author":"Wong","year":"2022","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.002_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.31726","article-title":"Administrative coding in electronic health care record-based Research of NAFLD: an expert panel consensus statement","volume":"74","author":"Hagstr\u00f6m","year":"2021","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.eprac.2024.08.002_bib16","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s11606-021-07197-3","article-title":"Nonalcoholic fatty liver disease underdiagnosis in primary care: what are we missing?","volume":"37","author":"Nielsen","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.eprac.2024.08.002_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"Easl clinical practice guidelines (cpgs) on non-invasive tests for evaluation of liver disease severity and prognosis- 2020 update","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.eprac.2024.08.002_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2024.08.002_bib19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1475-6773.2007.00822.x","article-title":"Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database","volume":"43","author":"Quan","year":"2008","journal-title":"Health Serv Res"},{"issue":"11","key":"10.1016\/j.eprac.2024.08.002_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.eprac.2024.08.002_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.20222","article-title":"Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality","volume":"6","author":"Vell","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.eprac.2024.08.002_bib22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement","volume":"328","author":"Force","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eprac.2024.08.002_bib23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.002_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.002_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eprac.2024.08.002_bib26","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.eprac.2024.08.002_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/ds17-0085","article-title":"Hypertension management in diabetes: 2018 update","volume":"31","author":"Passarella","year":"2018","journal-title":"Diabetes Spectr"},{"issue":"7","key":"10.1016\/j.eprac.2024.08.002_bib28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jama.2019.10298","article-title":"Association of smoking cessation with subsequent risk of cardiovascular disease","volume":"322","author":"Duncan","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eprac.2024.08.002_bib29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/ntr\/nty142","article-title":"Level of alcohol consumption and successful smoking cessation","volume":"21","author":"Lynch","year":"2019","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.002_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.002_bib31","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.002_bib32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.002_bib33","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3748\/wjg.v21.i5.1650","article-title":"Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index","volume":"21","author":"Pang","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.002_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12876-021-01824-3","article-title":"Waist-to-height ratio and non-alcoholic fatty liver disease in adults","volume":"21","author":"Sheng","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.002_bib35","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.231007","article-title":"Association between liver MRI proton density fat fraction and liver disease risk","volume":"309","author":"Xia","year":"2023","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.eprac.2024.08.002_bib36","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3390\/biomedicines10102416","article-title":"Waist-to-Hip ratio and inflammatory parameters are associated with risk of non-alcoholic fatty liver disease in patients with morbid obesity","volume":"10","author":"Borges-Canha","year":"2022","journal-title":"Biomedicines"},{"issue":"9756","key":"10.1016\/j.eprac.2024.08.002_bib37","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eprac.2024.08.002_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000244","article-title":"Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease","volume":"7","author":"Wong","year":"2023","journal-title":"Hepatol Commun"},{"issue":"11","key":"10.1016\/j.eprac.2024.08.002_bib39","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s11606-023-08093-8","article-title":"Real-world primary care data comparing ALT and FIB-4 in predicting future severe liver disease outcomes","volume":"38","author":"Schreiner","year":"2023","journal-title":"J\u00a0Gen Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.002_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/liv.15295","article-title":"FIB-4 and incident severe liver outcomes in patients with undiagnosed chronic liver disease: a Fine-Gray competing risk analysis","volume":"43","author":"Schreiner","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.eprac.2024.08.002_bib41","doi-asserted-by":"crossref","first-page":"e3452","DOI":"10.1002\/dmrr.3452","article-title":"Advanced liver fibrosis and the metabolic syndrome in a primary care setting","volume":"37","author":"Schreiner","year":"2021","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:15:15Z","timestamp":1778616915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24006487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1530891X24006487"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.08.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Objective Measures of Cardiometabolic Risk and Advanced Fibrosis Risk Progression in Primary Care Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}